Literature DB >> 16169085

Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion.

Eliza E Robertson1, Gary O Rankin.   

Abstract

The kidney is a key organ for promoting the excretion of drugs and drug metabolites. One of the mechanisms by which the kidney promotes excretion is via active secretion. Secretion of drugs and their metabolites from blood to luminal fluid in the nephron is a protein-mediated process that normally involves either the direct or indirect expenditure of energy. Renal transporters for organic anions are located in the proximal tubule segment of the nephron. The primary transporters of organic anions on the basolateral membrane (BLM) of proximal tubule cells are members of the organic anion transporter (OAT) family (mainly OAT1 and OAT3). The sulfate-anion antiporter 1 (SAT-1; hsat-1) may also contribute to organic anion transport at the basolateral membrane. On the apical membrane, the multi-drug resistance-associated protein 2 (MRP2) is an important transport protein to complete the secretion process. However, there are several transport proteins on the basolateral and apical membranes of proximal tubule cells in human kidneys that have not been fully characterized and whose role in the secretion of organic anions remains to be determined. This review will primarily focus on the human renal basolateral and apical membrane transporters for organic anions that may play a role in the excretion of drugs and drug metabolites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169085     DOI: 10.1016/j.pharmthera.2005.07.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  19 in total

1.  Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats.

Authors:  Brian T Hawkins; Scott M Ocheltree; Kristi M Norwood; Richard D Egleton
Journal:  Neurosci Lett       Date:  2006-11-15       Impact factor: 3.046

Review 2.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 3.  Physiology, structure, and regulation of the cloned organic anion transporters.

Authors:  C Srimaroeng; J L Perry; J B Pritchard
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

4.  Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia.

Authors:  Andrea Hahn; Tsuyoshi Fukuda; David Hahn; Tomoyuki Mizuno; Robert W Frenck; Alexander A Vinks
Journal:  Pharmacogenomics       Date:  2016-04-05       Impact factor: 2.533

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 6.  Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis.

Authors:  Sun-Young Ahn; Sanjay K Nigam
Journal:  Mol Pharmacol       Date:  2009-06-10       Impact factor: 4.436

7.  Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters.

Authors:  Xiao-Yan Chu; Yuexia Liang; Xiaoxin Cai; Karla Cuevas-Licea; Ronda K Rippley; Kelem Kassahun; Magang Shou; Matthew P Braun; George A Doss; M Reza Anari; Raymond Evers
Journal:  Pharm Res       Date:  2008-12-11       Impact factor: 4.200

8.  Organic anion transporters OAT1 and OAT4 mediate the high affinity transport of glutarate derivatives accumulating in patients with glutaric acidurias.

Authors:  Yohannes Hagos; Wolfgang Krick; Thomas Braulke; Chris Mühlhausen; Gerhard Burckhardt; Birgitta C Burckhardt
Journal:  Pflugers Arch       Date:  2008-03-26       Impact factor: 3.657

9.  Organic anion transporter 3 contributes to the regulation of blood pressure.

Authors:  Volker Vallon; Satish A Eraly; William R Wikoff; Timo Rieg; Gregory Kaler; David M Truong; Sun-Young Ahn; Nitish R Mahapatra; Sushil K Mahata; Jon A Gangoiti; Wei Wu; Bruce A Barshop; Gary Siuzdak; Sanjay K Nigam
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

10.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.